Cargando…
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis
BACKGROUND: Anal canal squamous cell carcinoma (ACSCC) is an exceedingly rare malignant neoplasm with challenges in sphincter preservation, treatment toxicities and long-term survival. Little is known concerning the activity of PD-1 antibodies in locally advanced ACSCC. This study reports on the eff...
Autores principales: | Xiao, WeiWei, Yuan, Yan, Wang, SuiHai, Liao, Zhidong, Cai, PeiQiang, Chen, BaoQing, Zhang, Rong, Wang, Fang, Zeng, ZhiFan, Gao, YuanHong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794813/ https://www.ncbi.nlm.nih.gov/pubmed/35095878 http://dx.doi.org/10.3389/fimmu.2021.798451 |
Ejemplares similares
-
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer
por: Hu, Yun, et al.
Publicado: (2022) -
Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
por: Wei, Chun, et al.
Publicado: (2023) -
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
por: Ott, P. A., et al.
Publicado: (2017) -
Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
por: Jiang, Ting, et al.
Publicado: (2021) -
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
por: Leidner, Rom, et al.
Publicado: (2021)